Signal
Celmatix raises $80M Series C to advance non-hormonal contraceptive and PCOS therapeutics
- Category
- Biotech & Pharma · Funding · Global
- Date
- March 14, 2026
- Source
- Endpoints News
Summary
Celmatix closes an $80M Series C led by RA Capital to push its lead non-hormonal contraceptive and PCOS candidate through IND-enabling studies.
Celmatix works in Endometriosis/PCOS and Sexual & Reproductive, and this round at Series C ($80M) is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- Endpoints News Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.